Bolus Pouch Feed Study

Sponsor
Nutricia UK Ltd (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05822557
Collaborator
(none)
30
15
1
19.1
2
0.1

Study Details

Study Description

Brief Summary

The primary aim of this study is to evaluate the impact of introducing a new enteral tube feed on health and feeding related quality of life. Secondary aims are to assess ease of use, liking, compliance, gastrointestinal tolerance, nutrient intake, anthropometric changes and safety.

Condition or Disease Intervention/Treatment Phase
  • Other: Bolus Pouch Feed
N/A

Detailed Description

Bolus enteral tube feeding (termed 'bolus feeding') is an increasingly common method of providing nutritional support to home enterally tube fed (HETF) patients, particularly those who are more active and/or require greater flexibility in their feeding regimen. However, current methods of bolus feeding are complex to administer, messy, may be unhygienic, and require and lead to a significant amount of plastic waste. Therefore, there is a clear need for a simpler and optimised way to provide bolus feeds. The aim of this study is to evaluate the impact of introducing a new enteral tube feed on health and feeding related quality of life, ease of use, liking, compliance, gastrointestinal tolerance, nutritional intake, anthropometry and safety. This is a prospective, longitudinal, 28-day intervention study with a 7-day baseline period.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
This is a prospective, longitudinal, 28-day intervention study with a 7-day baseline period.This is a prospective, longitudinal, 28-day intervention study with a 7-day baseline period.
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
A Study Evaluating a Newly Designed Nutritional Tube Feeding Pouch for Bolus Feeding in Adults
Anticipated Study Start Date :
Apr 1, 2023
Anticipated Primary Completion Date :
Nov 1, 2024
Anticipated Study Completion Date :
Nov 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Bolus Pouch Feed

A 250 ml feeding pouch containing 400 kcal.

Other: Bolus Pouch Feed
Following the 7-day baseline period, all patients will enter the 28-day intervention period, where they will receive the intervention feed daily. The feed prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management

Outcome Measures

Primary Outcome Measures

  1. Health and feeding related quality of life [Baseline to end of intervention (Day 35)]

    At baseline, and at the mid-point and end of the intervention period, health and feeding related quality of life will be assessed by the FACT-EQ questionnaire.

Secondary Outcome Measures

  1. Ease of administration [Baseline to end of intervention (Day 35)]

    At baseline, and at the mid-point and end of the intervention period, patients and dietitians will be asked to rate the ease of administering the enteral tube feed via a Likert-style questionnaire. Patients will also count the amount of feeding equipment required to administer the enteral feed at baseline, and at the midpoint and end of the intervention period.

  2. Liking of feeding method [Baseline to end of intervention (Day 35)]

    At baseline, and at the mid-point and end of the intervention period, patients will be asked to rate their liking of their usual feeding method or of the intervention feed, respectively via a 7-point Likert scale questionnaire.

  3. Gastrointestinal tolerance [Baseline to end of intervention (Day 35)]

    A standardised gastrointestinal (GI) tolerance questionnaire to capture perceived severity (none, mild, moderate or severe) of common gastrointestinal symptoms (diarrhoea, constipation, bloating, abdominal discomfort, vomiting and nausea) will be recorded at the end of each week. Information about bowel movements will also be collected using the Bristol Stool Chart©.

  4. Compliance [Baseline to end of intervention (Day 35)]

    Compliance with feed prescription will be assessed daily throughout the study by recording how much feed was received, to be recorded by the patient.

  5. Nutrient intake [Baseline to end of intervention (Day 35)]

    At baseline, and at the mid-point and end of the intervention period, the dietitian will conduct a 24-h dietary recall with the patient to record all food, drink and nutritional feeds provided in the 24 h prior. Trained research staff will subsequently analyse all records utilising a nutritional software package (Nutritics Professional v3.09, Nutritics, Ireland) for macro- and micro-nutrient intakes.

  6. Body weight (kg) [Baseline to end of intervention (Day 35)]

    At baseline and at the end of the intervention period, body weight (kg) will be measured using standard methods to the nearest 0.1 kg using a weighing scale without heavy clothing.

  7. Adverse Events [Baseline to end of intervention (Day 35)]

    All adverse events will be recorded throughout the study.

Eligibility Criteria

Criteria

Ages Eligible for Study:
16 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • ≥16 years of age

  • Using or requiring an enteral tube feed as part of nutritional management plan

  • Using or about to use bolus tube feeding methods at least once daily

  • Expected to receive at least 400 kcal/day from the intervention feed

  • Written or electronic informed consent from patient, or verbally given consent countersigned by a witness for those physically unable to sign.

Exclusion Criteria:
  • Parenteral nutrition contributing more than 70% of total energy requirements

  • Patients with major hepatic dysfunction (i.e., decompensated liver disease)

  • Patients with major renal dysfunction [i.e., requiring filtration or stage 4/5 chronic kidney disease (CKD)]

  • Patients receiving inpatient care

  • Participation in other clinical intervention studies within 2 weeks of this study

  • Adults lacking mental capacity to consent

  • Allergy to any study product ingredients

  • Investigator concern regarding ability or willingness of patient to comply with the study requirements.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospitals Sussex NHS Foundation Trust Brighton United Kingdom
2 Cambridge University Hospitals NHS Foundation Trust Cambridge United Kingdom
3 University Hospitals Coventry and Warwickshire NHS Trust Coventry United Kingdom
4 County Durham and Darlington NHS Foundation Trust Darlington United Kingdom
5 NHS Tayside Dundee United Kingdom
6 Royal Surrey NHS Foundation Trust Guildford United Kingdom
7 Betsi Cadwaladr University Health Board Holywell United Kingdom
8 Calderdale & Huddersfield NHS Foundation Trust Huddersfield United Kingdom
9 Leicestershire Partnership NHS Trust Leicester United Kingdom
10 North East London NHS Foundation Trust London United Kingdom
11 Northumbria Healthcare NHS Foundation Trust Newcastle Upon Tyne United Kingdom
12 Nottingham University Hospitals NHS Trust Nottingham United Kingdom
13 Sheffield Teaching Hospitals NHS Foundation Trust Sheffield United Kingdom
14 Southern Health NHS Foundation Trust Southampton United Kingdom
15 South Warwickshire NHS Foundation Trust Warwick United Kingdom

Sponsors and Collaborators

  • Nutricia UK Ltd

Investigators

  • Study Chair: Rebecca Stratton, PhD, Nutricia UK Ltd

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Nutricia UK Ltd
ClinicalTrials.gov Identifier:
NCT05822557
Other Study ID Numbers:
  • BOPFS2020
First Posted:
Apr 20, 2023
Last Update Posted:
Apr 20, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 20, 2023